Phase I study evaluating safety and tolerability of SurVaxM in patients with survivin-expressing recurrent malignant gliomas

Trial Profile

Phase I study evaluating safety and tolerability of SurVaxM in patients with survivin-expressing recurrent malignant gliomas

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs SVN53-67-M57-KLH peptide vaccine (Primary)
  • Indications Glioma
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Apr 2017 Results assessing specific exosomes correlated with disease progression, presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 19 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top